perillyl alcohol

Small moleculeexperimental

Perilla alcohol is a naturally occurring monoterpene related to limonene. It is isolated from the essential oils of lavender, peppermint, spearmint, cherries, celery seeds, and several other plants. It has been used topically as a mosquito repellant and in toiletries and may be touted as a constituent of natural products such as tart cherry juice. Perillyl alcohol has demonstrated antiangiogenesis and anticancer effects in vitro. Purported mechanism of action is suppression of the synthesis of small G proteins, including RAS, thereby arresting tumor cells in the G1 phase of the cell cycle. Early clinical studies did not efficacy in prostate, ovarian or breast cancer, probably due to bad pharmacokinetic properties and toxicity after oral administration. More recent preliminary studies found intranasal delivery in patients with malignant gliomas to be well-tolerated and effective, with one study reporting tumor size regression, and another reporting increased overall survival and no side effects after long-term use. — NCATS

Clinical trial activity

9 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Oct 1, 1996 (NCT00002862)

Timeline

1990s

  1. Jan 1, 1996

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 1998

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Loading structure…

SMILES

CC(=C)[C@H]1CCC(CO)=CC1
Mol. weight
152.2334 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1-cyclohexene-1-methanol, 4-(1-methylethenyl)-, (4s)-
  • 4-isopropenyl-cyclohex-1-ene-1-methanol
  • cyclohex-1-ene-1-methanol, 4(1-methylethenyl)
  • dihydrocuminyl alcohol
  • nsc 641066
  • perilla alcohol
  • perilla alcohol, (r)-isomer
  • perilla alcohol, (s)-isomer
  • perillyl alcohol
  • perillyl alcohol
  • perillyl alcohol
  • (-)-p-mentha-1,8-dien-7-ol
  • p-mentha-1,8-dien-7-ol
  • (s)-perillyl alcohol

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06357377Phase 1Dec 31, 2024NeOnc Technologies
NCT05023018Phase 2Oct 1, 2021NeOnc Technologies
NCT02704858Phase 1/Phase 2 (Phase 2)Apr 1, 2016ClinDatrix, Inc., NeOnc Technologies
NCT00608634Phase 2May 1, 2004National Cancer Institute (NCI), State of Arizona, University of Arizona
NCT00022425Phase 1Jun 1, 2001National Cancer Institute (NCI), University of Rochester
NCT00003769Phase 2Feb 1, 1999Indiana University, National Cancer Institute (NCI)
NCT00003219Phase 2May 1, 1998National Cancer Institute (NCI), University of Wisconsin
NCT00003238Phase 2Feb 1, 1998National Cancer Institute (NCI), University of Wisconsin
NCT00002862Phase 1Oct 1, 1996National Cancer Institute (NCI), Yale University
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government6121996
NeOnc TechnologiesFor profit3322016
University of WisconsinAcademic/Hospital2211998
ClinDatrix, Inc.For profit1012016
Indiana UniversityAcademic/Hospital1111999
State of ArizonaGovernment1012004
University of ArizonaAcademic/Hospital1112004
University of RochesterAcademic/Hospital1112001
Yale UniversityAcademic/Hospital1011996
9 organizations
Page 1 / 1